Kymera Therapeutics Inc (KYMR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kymera Therapeutics Inc (KYMR) has a cash flow conversion efficiency ratio of -0.058x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-88.84 Million) by net assets ($1.54 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See KYMR net asset quality index to measure how much of total assets are equity-financed.
Kymera Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Kymera Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Kymera Therapeutics Inc total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Kymera Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kymera Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Norwegian Cruise Line Holdings Ltd
NYSE:NCLH
|
0.334x |
|
IAMGold Corporation
TO:IMG
|
0.078x |
|
KAWASAKI KISEN K. ADR/1/2
F:KLI
|
N/A |
|
CITIC Metal Co. Ltd. A
SHG:601061
|
N/A |
|
Frontline Ltd
NYSE:FRO
|
0.113x |
|
Hengyi Petrochemical Co Ltd
SHE:000703
|
0.025x |
|
DISCOVERY LTD(UNSP.ADR)/3
F:D3H0
|
N/A |
|
Orion Oyj B
HE:ORNBV
|
0.086x |
Annual Cash Flow Conversion Efficiency for Kymera Therapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Kymera Therapeutics Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Kymera Therapeutics Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.58 Billion | $-232.89 Million | -0.147x | +36.66% |
| 2024-12-31 | $835.62 Million | $-194.50 Million | -0.233x | +10.59% |
| 2023-12-31 | $394.97 Million | $-102.83 Million | -0.260x | +16.64% |
| 2022-12-31 | $490.15 Million | $-153.09 Million | -0.312x | -11.33% |
| 2021-12-31 | $459.64 Million | $-128.95 Million | -0.281x | -190.37% |
| 2020-12-31 | $283.89 Million | $88.13 Million | 0.310x | +229.01% |
| 2019-12-31 | $-74.41 Million | $17.91 Million | -0.241x | -146.39% |
| 2018-12-31 | $-34.44 Million | $-17.86 Million | 0.519x | -- |
About Kymera Therapeutics Inc
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CR… Read more